We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Stockholm, Sweden

ESTRO 2026

Session

Sunday
May 17
09:00 - 10:00
T2
Urological cancers 2
Stefano Arcangeli, Italy;
Wojciech Kamzol, Poland
Mini-Orals
Clinical
09:00 - 10:00
One-year cumulative toxicity in 25 prostate cancer patients treated with single fraction (24 Gy) urethra-sparing radiosurgery (PRO-FAST-NCT05936736 )
Andrei Fodor, Italy
-4879
09:00 - 10:00
Long-term toxicity and PSA dynamics in the initial cohort of SABR-Dual: Two-fraction stereotactic radiotherapy for localized prostate (NCT06027892)
Elisha Fredman, Israel
-804
09:00 - 10:00
Correlation Between PSMA PET/CT and Artera-AI Prostate Test in Intermediate Risk Prostate Cancer Patients
Olivia Jo, Australia
-1793
09:00 - 10:00
Nationwide analysis of lower GI toxicity after prostate radiotherapy: comparison of radiotherapy modalities using National Health Registry
Irena Koniarova, Czech Republic
-4941
09:00 - 10:00
Daily Adaptive RadioTherapy in Postoperative HypofrActionated Salvage radiothERapy for prostate cancer patients (DART-PHASER): preliminary results
Luca Nicosia, Italy
-3159
09:00 - 10:00
Radiotherapy Management of Muscle Invasive Bladder Cancer: Re-evaluation of UK Practice against The Royal College of Radiologists Consensus Statements
Mohini Varughese, United Kingdom
-1412
09:00 - 10:00
Long-term oncological outcomes of radical cystectomy versus bladder-preserving therapy in muscle invasive bladder cancer.
Katharina Brück, The Netherlands
-1386
09:00 - 10:00
IMPT vs. IMRT in High-Risk Prostate Cancer: Early Safety outcomes from Propensity-Matched Comparison of Two Prospective Studies: The PROTO-PRIME Study
Srinivas Chilukuri, India
-2585